Results 301 to 310 of about 281,052 (341)
FRMD8 inhibits tumor metastasis in BRCA1-associated TNBC by negatively regulating tmTNF-α. [PDF]
Cell Mol Biol LettXu J +5 more
europepmc +1 more source
RETRACTION: Treatment with β-elemene combined with paclitaxel inhibits growth, migration, and invasion and induces apoptosis of ovarian cancer cells by activation of STAT-NF-κB pathway. [PDF]
Braz J Med Biol Reseuropepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
2019
Paclitaxel is the first microtubule-stabilizing agent identified and considered to be the most significant advance in chemotherapy of the past two decades. It is considered one of the most widely used antineoplastic agents with broad activity in several cancers including breast cancer, endometrial cancer, non-small-cell lung cancer, bladder cancer, and
Fulwah Yahya, Alqahtani +4 more
openaire +2 more sources
Paclitaxel is the first microtubule-stabilizing agent identified and considered to be the most significant advance in chemotherapy of the past two decades. It is considered one of the most widely used antineoplastic agents with broad activity in several cancers including breast cancer, endometrial cancer, non-small-cell lung cancer, bladder cancer, and
Fulwah Yahya, Alqahtani +4 more
openaire +2 more sources
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1994
Paclitaxel is a novel antineoplastic that effects cytotoxicity by promoting intracellular tubulin polymerization and stabilizes abnormal microtubule structures against depolymerization. Although its clinical development had been hampered by misconceptions about its pharmacology, its scarcity, difficulties extracting it from its natural source ...
D R, Kohler, B R, Goldspiel
openaire +2 more sources
Paclitaxel is a novel antineoplastic that effects cytotoxicity by promoting intracellular tubulin polymerization and stabilizes abnormal microtubule structures against depolymerization. Although its clinical development had been hampered by misconceptions about its pharmacology, its scarcity, difficulties extracting it from its natural source ...
D R, Kohler, B R, Goldspiel
openaire +2 more sources
The clinical development of paclitaxel and the paclitaxel/carboplatin combination
European Journal of Cancer, 1998Paclitaxel and carboplatin have nonoverlapping toxicities with a broad range of clinical activity. The combination of escalating dose paclitaxel and carboplatin dosed to a fixed area under the curve (AUC) was explored in a series of phase I studies.
Gary Schwartz +6 more
openaire +3 more sources